Evidence map›Paper›PMID 41053522›Full record

ArticleThe Journal of antibiotics2025

Two novel cytotoxic pyrrole-2,5-dione xylogonone acids A and B isolated from the fungus Xylogone Sphaerospora.

Xiao Ren, Pengran Cao, Jingtong Zhu, Yeying Li, Xiaolan Cui, Tengyu Wang, Jiawang Li, Wenbin Shen, Xuexia Zhang, Lijie Wang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiao Ren *New Drug Research and Development Center, North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Shijiazhuang Microbial Drug Technology Innovation Center, Shijiazhuang, PR China.
Pengran Cao *New Drug Research and Development Center, North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Shijiazhuang Microbial Drug Technology Innovation Center, Shijiazhuang, PR China.
Jingtong ZhuNew Drug Research and Development Center, North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Shijiazhuang Microbial Drug Technology Innovation Center, Shijiazhuang, PR China.
Yeying LiNew Drug Research and Development Center, North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Shijiazhuang Microbial Drug Technology Innovation Center, Shijiazhuang, PR China.
Xiaolan CuiNew Drug Research and Development Center, North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Shijiazhuang Microbial Drug Technology Innovation Center, Shijiazhuang, PR China.
Tengyu WangNew Drug Research and Development Center, North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Shijiazhuang Microbial Drug Technology Innovation Center, Shijiazhuang, PR China.
Jiawang LiNew Drug Research and Development Center, North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Shijiazhuang Microbial Drug Technology Innovation Center, Shijiazhuang, PR China.
Wenbin ShenNew Drug Research and Development Center, North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Shijiazhuang Microbial Drug Technology Innovation Center, Shijiazhuang, PR China.
Xuexia ZhangNew Drug Research and Development Center, North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Shijiazhuang Microbial Drug Technology Innovation Center, Shijiazhuang, PR China.
Lijie WangNew Drug Research and Development Center, North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Shijiazhuang Microbial Drug Technology Innovation Center, Shijiazhuang, PR China.
Xinhua LuNew Drug Research and Development Center, North China Pharmaceutical Group Corporation, National Microbial Medicine Engineering and Research Center, Hebei Industry Microbial Metabolic Engineering & Technology Research Center, Shijiazhuang Microbial Drug Technology Innovation Center, Shijiazhuang, PR China. luxinhua89@yeah.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two previously unreported compounds, designated pyrrole-2, 5-dione xylogonone acids A (1) and B (2), were isolated from the ascomycete fungus Xylogone Sphaerospora. These metabolites feature a rare, highly functionalized pyrrole-2,5-dione. Their chemical structures were determined through detailed analysis of NMR and HRMS data, with the structure of compound 1 further validated by X-ray crystallographic analysis. Both compounds exhibited distinct cytotoxic profiles against several human cancer cell lines, including A549, MDA-MB-231, HepG2, HT-29, K562, and SW620, with IC

Indexed as

Antineoplastic AgentsAscomycotaPyrrolesCell Line, TumorCrystallography, X-RayDrug Screening Assays, AntitumorHumansInhibitory Concentration 50Magnetic Resonance SpectroscopyMolecular StructureAntineoplastic AgentsPyrroles

Identifiers

PMID41053522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.